Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 2/20 | 0.88 |
| ▸ | LCK | P06239 | 1/20 | 0.88 |
| ▸ | FYN | P06241 | 1/20 | 0.88 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | MMP12 | P39900 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL5867869 | 1.00 | FFAR3 (0.88) | FFAR3LCKFYNLMNATSHR | |
| Acetic Acid SCHEMBL234816 | 1.00 | FFAR3 (0.88) | FFAR3LCKFYNLMNATSHR | |
| Acetic Acid SCHEMBL11858088 | 1.00 | FFAR3 (0.88) | FFAR3LCKFYNLMNATSHR | |
| Acetic Acid SCHEMBL536985 | 1.00 | — | — | |
| Acetic Acid SCHEMBL11857925 | 1.00 | FFAR3 (0.88) | FFAR3LCKFYNLMNATSHR | |
| Acetic Acid SCHEMBL226015 | 1.00 | — | — | |
| Acetic Acid SCHEMBL52435 | 1.00 | — | — | |
| Acetic Acid SCHEMBL4124082 | 1.00 | — | — | |
| Acetic Acid SCHEMBL51762 | 1.00 | — | — | |
| Acetic Acid SCHEMBL11776704 | 1.00 | FFAR3 (0.88) | FFAR3LCKFYNLMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240101553-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| EP-3710439-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-02-15 | — | — | EP | disclosed |
| US-11267812-B2 | KRAS G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2022-03-08 | — | — | US | disclosed |
| US-11078193-B2 | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | JANSSEN SCIENCES IRELAND UC (IE) | 2021-08-03 | — | — | US | disclosed |
| EP-3458445-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3710439-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-09-23 | — | — | EP | disclosed |
| US-20200262837-A1 | KRAS G12C INHIBITORS | ARRAY BIOPHARMA INC. | 2020-08-20 | — | — | US | disclosed |
| US-10689377-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2020-06-23 | — | — | US | disclosed |
| US-10633381-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2020-04-28 | — | — | US | disclosed |
| US-10125134-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2018-11-13 | — | — | US | disclosed |
| EP-3102572-B1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2018-10-24 | — | — | EP | disclosed |
| US-20180072723-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2018-03-15 | — | — | US | disclosed |
| WO-2017201161-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2017-11-23 | — | — | WO | disclosed |
| EP-3102572-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | Janssen Sciences Ireland UC (IE) | 2016-12-14 | — | — | EP | disclosed |
| US-20160347741-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC | 2016-12-01 | — | — | US | disclosed |
| WO-2015118057-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2015-08-13 | — | — | WO | disclosed |
| US-20070154561-A1 | Metal oxide particle and its uses | NIPPON SHOKUBAI CO., LTD. | 2007-07-05 | — | — | US | disclosed |
| EP-1716077-A2 | METAL OXIDE PARTICLE AND ITS USES | Nippon Shokubai Co.,Ltd. (JP) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005076752-A2 | METAL OXIDE PARTICLE AND ITS USES | NIPPON SHOKUBAI CO., LTD. (JP) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10633381-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | FFAR3 3355/4885LCK 1194/4885FYN 3020/4885 |
| US-20200262837-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | FFAR3 3355/4885LCK 1194/4885FYN 3020/4885 |
| US-11267812-B2 | KRAS G12C inhibitors | KRAS, NRAS, HRAS | FFAR3 3355/4885LCK 1194/4885FYN 3020/4885 |
| US-10125134-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | FFAR3 3355/4885LCK 1194/4885FYN 3020/4885 |
| US-11078193-B2 | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | RB1, SRR, RRP12 | FFAR3 2734/4885LCK 3515/4885FYN 4110/4885 |
| US-10689377-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | FFAR3 3355/4885LCK 1194/4885FYN 3020/4885 |
| US-20240101553-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | FFAR3 3355/4885LCK 1194/4885FYN 3020/4885 |
| US-20180072723-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | FFAR3 3355/4885LCK 1194/4885FYN 3020/4885 |
| US-20160347741-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | RB1, SRR, RRP12 | FFAR3 2734/4885LCK 3515/4885FYN 4110/4885 |
| US-20230373999-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | FFAR3 3355/4885LCK 1194/4885FYN 3020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.